All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 15 January 2019, the results of the randomized, multicenter, phase III trial, AHL2011 (NCT01358747) were published in The Lancet Oncology by Rene-Olivier Casasnovas from the Dijon Bourgogne University Hospital, Dijon, FR, and colleagues.
The aim of this non-inferiority phase III trial was to investigate whether PET-adapted treatment for newly-diagnosed advanced Hodgkin lymphoma (HL) patients results in better disease management and treatment. The authors specifically assessed if PET monitoring would allow switching from increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) to oxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in early responders, so as to minimise BEACOPP-associated toxicity without loss of disease control. The primary endpoint was investigator-assessed progression-free survival (PFS). The non-inferiority margin of this study was 10%, to show non-inferiority of PET-adapted treatment as compared to standard care with 80% power and 2.5% alpha. Secondary endpoints included overall survival (OS), event-free survival (EFS), and disease-free survival.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox